CellTrust Victorious at U.S. Patent and Trademark Office Against Third-Party Challenges

USPTO Rejects Third-Party Challenge and Confirms Patentability of CellTrust’s Patented Technology

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--CellTrust today reaffirms the company received Ex Parte Reexamination Certificates from the U.S. Patent and Trademark Office in August 2024, thus successfully defending the challenges to the original CellTrust patent claims and confirming the patentability of the new CellTrust patent claims.

“Since it was founded, CellTrust has invested significantly to patent and protect its inventions. As an inventor and as the co-founder of CellTrust, we will continue to promote and protect our inventions so that our innovation and innovators are recognized and rewarded appropriately,” said Sean Moshir, CellTrust Chairman and CEO.

CellTrust received Ex Parte Reexamination Certificates from the USPTO for claims of U.S. Patent No.9,775,012 (“the ’012 Patent”) and claims of U.S. Patent No. 10,778,837 (“the ’837 Patent”).

The USPTO confirmed the patentability of new patent claims and rejected the third party’s challenge to the original patent claims, which remain the subject of other ongoing litigation.

For more information:

The Ex Parte Reexamination Certificates and USPTO opinion can be accessed at the USPTO Patent Center website: https://patentcenter.uspto.gov

About CellTrust Corporation

CellTrust Corporation is a mobile security and communications compliance leader for financial services, government, and other highly regulated sectors. CellTrust’s mobile communication platform and flagship SL2™ Enterprise Capture streamline mobile communication compliance through SMS/text, chat and voice capture, moderation, gateway hold, retention, and eDiscovery. CellTrust helps organizations meet regulatory recordkeeping requirements, such as SEC, CFTC, FINRA, SOX, FCA, MiFID II, FOIA, Sunshine Laws, Public Records Laws, and HIPAA. CellTrust is a member of the Microsoft Intelligent Security Association. www.celltrust.com

©2025 CellTrust Corporation. All rights reserved.